Age: 93.0
Sex: M
Vaccine: COVID19-2
Symptoms: Diplopia, Pseudostroke
Clinical narrative: He had previously experienced a mini-stroke that may have affected muscles around his eyes; After receiving a recent booster of his Moderna COVID vaccine he experienced double vision (approximately 3-4 weeks prior to today).; This spontaneous case was reported by a non-health professional and describes the occurrence of PSEUDOSTROKE (He had previously experienced a mini-stroke that may have affected muscles around his eyes) in a 93-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In 2023, the patient experienced DIPLOPIA (After receiving a recent booster of his Moderna COVID vaccine he experienced double vision (approximately 3-4 weeks prior to today).). On an unknown date, the patient experienced PSEUDOSTROKE (He had previously experienced a mini-stroke that may have affected muscles around his eyes) (seriousness criterion medically significant). At the time of the report, PSEUDOSTROKE (He had previously experienced a mini-stroke that may have affected muscles around his eyes) and DIPLOPIA (After receiving a recent booster of his Moderna COVID vaccine he experienced double vision (approximately 3-4 weeks prior to today).) outcome was unknown.            Concomitant Medication use information was not provided by reporter. Treatment Medication use information was not provided by reporter.   Company Comment: This is a spontaneous case concerning a 93-year-old, male patient with no reported medical history, who experienced the serious (due to medically significant) unexpected event of Pseudostroke and the non-serious event of diplopia. The event Diplopia occurred approximately 3-4 weeks after a booster dose of mRNA-1273 .222 vaccine received as a dose of COVID-19 vaccination schedule and the event Pseudostroke occurred on an unknown date (onset dated, dose number and date of administration were not provided). Onset dates, clinical course, supportive diagnostic procedures, treatment, medical history, concomitant medications and outcome, were not provided. The benefit-risk relationship of mRNA-1273.222 vaccine is not affected by this report.; Reporter's Comments: This is a spontaneous case concerning a 93-year-old, male patient with no reported medical history, who experienced the serious (due to medically significant) unexpected event of Pseudostroke and the non-serious event of diplopia. The event Diplopia occurred approximately 3-4 weeks after a booster dose of mRNA-1273 .222 vaccine received as a dose of COVID-19 vaccination schedule and the event Pseudostroke occurred on an unknown date (onset dated, dose number and date of administration were not provided). Onset dates, clinical course, supportive diagnostic procedures, treatment, medical history, concomitant medications and outcome, were not provided. The benefit-risk relationship of mRNA-1273.222 vaccine is not affected by this report.